[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"summary","before":"\"Revolution Medicines' tri-complex inhibitor. Phase 1/2: median OS ~14.5 months in second-line pancreatic cancer versus historical ~6 months. RASolute 302 (second-line PDAC) supported FDA approval on 26 August 2026 as...","after":"\"Daraxonrasib is Revolution Medicines' tri-complex inhibitor. Phase 1/2: median OS ~14.5 months in second-line pancreatic cancer versus historical ~6 months. RASolute 302 (second-line PDAC) supported FDA approval on 2..."}]},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","commit":"9cbf031695","date":"2026-09-08","author":"Jude Gomila","message":"Daraxonrasib approved (Rasonque, FDA 26 Aug 2026); logos for new companies and sources","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"brand","after":"\"Rasonque\""},{"field":"status","before":"\"phase-3\"","after":"\"approved\""},{"field":"tldr","before":"\"A drug that blocks all active RAS variants, in a pivotal trial for pancreatic cancer, where KRAS drives 90% of tumours.\"","after":"\"The first drug that blocks all active RAS variants, approved by the FDA in August 2026 for metastatic pancreatic cancer, where KRAS drives 90% of tumours.\""},{"field":"summary","before":"\"Revolution Medicines' tri-complex inhibitor. Phase 1/2: median OS ~14.5 months in second-line pancreatic cancer versus historical ~6 months. RASolute 302 phase 3 (second-line PDAC) fully enrolled; RASolute 303 (first...","after":"\"Revolution Medicines' tri-complex inhibitor. Phase 1/2: median OS ~14.5 months in second-line pancreatic cancer versus historical ~6 months. RASolute 302 (second-line PDAC) supported FDA approval on 26 August 2026 as..."},{"field":"approvals","after":"[{ region: \"US\", year: 2026, indication: \"Metastatic pancreatic cancer (previously treated)\", note: \"Rasonque, 26 August 2026\" }]"},{"field":"links","after":"[{ label: \"FDA novel drug approvals 2026\", url: \"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026\" }]"}]},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/drugs.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"code"},{"field":"modality"},{"field":"asOf"},{"field":"status"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"}]}]